Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. (VSTM) on May 22, 2025. The filing covers the results of the Company's 2025 Annual Meeting of Stockholders held on May 22, 2025, in Needham, Massachusetts, and provides an update on the RAMP 205 Phase 1/2 clinical trial for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events and clinical trial developments rather than financial performance.
Material Changes and Corporate Actions
- Director Elections: Stockholders elected John Johnson, Michael Kauffman, and Eric Rowinsky as Class I directors to serve until the 2028 annual meeting.
- Accounting Firm Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the current fiscal year.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers.
Clinical Trial Updates and Outlook
The Company announced updated safety and efficacy results from the RAMP 205 trial evaluating the combination of avutometinib and defactinib with standard of care in first-line metastatic PDAC.
- Trial Status: As of April 25, 2025, 60 patients were treated across five dose regimens.
- Efficacy Results: In dose level 1, 83% (10/12) of patients achieved partial responses. Across all five dose cohorts, 92% (48/52) of efficacy-evaluable patients showed tumor reduction.
- Safety Profile: Adverse events remained consistent with the previously announced profile with no new safety signals.
- Next Steps: Dose level 1 was selected as the recommended Phase 2 dose. The Company is enrolling up to 29 patients in the expansion cohort and plans to discuss results at an investor event on June 2, 2025.
- Future Plans: The Company is developing plans for a registrational Phase 3 front-line metastatic PDAC trial to begin in 2026.
Investor Verification Checklist
- Verify the specific dosing schedule and patient demographics for the RAMP 205 dose level 1 cohort.
- Confirm the timeline and enrollment criteria for the upcoming Phase 3 trial planned for 2026.
- Review the full text of the press release (Exhibit 99.1) for detailed safety data and adverse event specifics.
- Monitor the investor research and development event scheduled for June 2, 2025, for further data presentation.